GlassScriptPhysician profile
Vineet Prasad
NPI 1609902493
$1,331.05
in general payments reported to CMS, 2019-2025
14 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.06 · 2021: $39.63 · 2022: $55.40 · 2023: $239 · 2024: $474 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.28 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pharmacosmos Therapeutics INC. | $125.00 | 2025 | Monoferric |
| Amgen INC. | $96.52 | 2021-2023 | Tavneos |
| Vifor Pharma, INC. | $82.24 | 2023-2025 | Veltassa |
| Pfizer INC. | $81.25 | 2023-2024 | |
| Glaxosmithkline, LLC. | $23.54 | 2025 | Arexvy, Shingrix |
| Calliditas Therapeutics US INC. | $18.06 | 2025 | Tarpeyo |
| Forte Bio-Pharma LLC | $17.80 | 2025 | Prolate, Nalocet, Tanlor |
| Idorsia Pharmaceuticals US INC | $15.50 | 2022 | |
| Lilly USA, LLC | $15.03 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $14.64 | 2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $14.06 | 2020 | |
| Novo Nordisk INC | $13.66 | 2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.